2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why.
Shares of SAGE Therapeutics Inc. (NASDAQ: SAGE) are rocketing higher today in response to positive clinical trial data for a postpartum depression candidate. Investors are pushing up Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) stock in hope that a similar candidate will succeed in an ongoing study as well. As of 10:50 a.m. EST, Sage and Marinus have risen 50.2% and 16.8%, respectively.
In September, after brexanolone failed to show a significant benefit for patients who suffer persistent seizures, enthusiasm for the drug sank. That loss gave the stock extra room to run following today's announcement that brexanolone hit its main goals in a phase 3 trial designed to support applications for the treatment of moderate and severe postpartum depression (PPD).
Image Source: Getty Images.
Source: Fool.com
Sage Therapeutics Inc. Aktie
Leichtes Buy-Überwiegen bei Sage Therapeutics Inc. im Vergleich zu Sell-Einschätzungen.
Das von der Community festgelegte Kursziel für Sage Therapeutics Inc. von 21 € würde den aktuellen Kurs von 7.16 € mehr als verdoppeln.
